Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small
On November 22nd, the Food and Drug Administration (FDA) approved the world’s first gene therapy for hemophilia B; Hemgenix (etranacogene dezaparvovec). Hemgenix will have a list price of $3.5 million per use. This sets a new record for the most expensive single-use gene therapy in the U.S. In…#icer #phase3 #fda #factorix #instituteforclinicalandeconomicrevi #cslbehring #hemgenixs #foodanddrugadministration #dutch #etranacogenedezaparvovec
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Budgets | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Haemophilia | Health | Hemophilia | Netherlands Health